Drugs / KHK4951
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04594681 | Sep 2020 → Aug 2022 | wet macular degeneration | Kyowa Kirin, Inc. | Terminated | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT06116890 | Jan 2024 → Aug 2026 overdue | wet macular degeneration | Kyowa Kirin, Inc. | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06116916 | Jan 2024 → Aug 2026 overdue | diabetic macular edema | Kyowa Kirin, Inc. | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KHK4951 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06116916 ↗ |
| Action | Inhibit | “KHK4951, a Vascular Endothelial Growth Factor Receptor Inhibitor” NCT06116890 ↗ |
| Route | Other | “KHK4951 eye drops” NCT06116890 ↗ |